Top Markets
#1 MowCat MowCat +49.00%
#2 Velvet Velvet +25.26%
#3 Audiera Audiera +25.23%
#4 Bermuda Shorts Bermuda Shorts +24.30%
#5 Quack AI Quack AI +21.46%
#6 Derive Derive +18.79%
#7 aPriori aPriori +17.89%
#8 Biconomy Biconomy +16.63%
#9 SkyAI SkyAI +14.17%
#10 Geodnet Geodnet +13.59%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd.

GLMD
Rank in Stocks #35178
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the... Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Share Price
$0.5225
Last synced: 2026-08-14
Market Cap
$4.32M
Change (1 day)
-1.60%
Change (1 year)
-63.72%
Country
IL
Trade Galmed Pharmaceuticals Ltd. (GLMD)

Category

Healthcare
Operating Margin for Galmed Pharmaceuticals Ltd. (GLMD)
Operating Margin as of 2026 TTM: 0.00%
According to Galmed Pharmaceuticals Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Galmed Pharmaceuticals Ltd. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.